Chromogranin A Expression in Patients With Hormone Naïve Prostate Cancer Predicts the Development of Hormone Refractory Disease
Alfredo Berruti(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Luigi Dogliotti(Aarhus University Hospital), Roberto Mario Scarpa(University of Turin), Enrico Bollito(Prostate Cancer UK), Alessandra Mosca(Candiolo Cancer Institute), Andrea Saini(University of Turin), Federica Vana(University of Turin), M. Torta(Prostate Cancer UK), F. Porpiglia(Ospedale San Luigi Gonzaga), Marcello Tucci(University of Turin), Cecilia Maria Cracco(University of Turin), Mauro Papotti(University of Turin), Lucianna Russo(Prostate Cancer UK), Alberto Angeli(Ospedale San Luigi Gonzaga), Susanna Cappia(University of Turin)
Cited by 89
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: Indications, Complications, and Outcomes in 5803 Patients
|Journal of Endourology|2011|818
A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery
|Annals of Surgery|2005|688